Search bioRxiv⌕ Search

Biology subjects

Ungaro, F.

Publications and source records attributed to Ungaro, F..

3 recordsLinked to original sources

RNA assignment and segmentation geometry in Visium HD profiles of fibrostenotic Crohn's disease

Retrospective reuse of spatial transcriptomics often starts from a deposited bin-level Seurat object rather than the inputs needed to revisit upstream molecular processing. We tested whether image segmentation could support a defensible cell-like reconstruction under this constraint in two complete H&E-stained intestinal sections from a Visium HD study of Crohn's disease-associated fibrostenosis (GSE302569). The available data comprised 18,085 genes, 988,942 original 8 {micro}m bins and 179,596,575 UMIs. We evaluated 20 segmentation configurations in the preserved image coordinate system using a common bin-centre assignment rule, without restarting Space Ranger or introducing higher-resolution expression. RNA assignment ranged from 0% to 74.68% in CD1 and 0% to 64.05% in CD2. Expansion increased recovery but did not eliminate merged regions, straight boundaries or within-bin ambiguity; approximately 70-73% of InstanSeg brightfield nuclear regions received no assigned RNA. All 38 non-empty configuration-slice combinations underwent native full-mode RCTD against the same nine-group scIBD reference. Mean slice-level RNA recovery was negatively associated with primary-component dominance across 19 configurations (descriptive Spearman {rho} = -0.77). Neither dominant-call agreement nor concentrated RCTD support validates boundaries or cell identity. The observed limitations in RNA recovery, region geometry, and compositional support did not establish any tested configuration as a reliable single-cell reconstruction from these inputs. The findings identify limitations of retrospective single-cell reconstruction from the available binned inputs, not the impossibility of cell-resolved analysis from suitable original data.

bioinformatics↗

Suppression of YAP/TAZ molecular targets by epigenetic editing interferes with GBM growth and invasiveness

Glioblastoma (GBM) is a highly aggressive brain tumor characterized by extensive heterogeneity, diffuse invasion, and recurrence despite multimodal therapy. Aberrant transcriptional programs driven by oncogenic signaling pathways sustain GBM growth, stemness, and therapy resistance, yet targeting individual molecular nodes has yielded limited clinical benefit. Here, we introduce a transcriptional rewiring strategy based on an engineered epigenetic silencer factor (ESF) targeting the YAP/TAZ-TEAD axis. We developed a TEAD1 Epigenetic Silencer (TES) by fusing the DNA-binding domain of TEAD1 to repressive epigenetic modules. TES selectively binds TEAD genomic targets and imposes stable transcriptional repression of YAP/TAZ-dependent gene programs through chromatin remodeling and DNA methylation. Genome-wide analyses revealed that TES preserves TEAD1 DNA-binding specificity while converting an oncogenic transcriptional platform into a repressive state. Functionally, TES impaired proliferation, induced cell death, and reduced migratory and invasive properties in glioma cell lines and patient-derived cancer stem-like cells. In vivo, TES significantly reduced tumor growth in orthotopic GBM xenograft models and enhanced the therapeutic efficacy of temozolomide. Importantly, TES was well tolerated by normal neural cells in vitro and in the adult mouse brain in vivo. These findings establish TES as a proof-of-concept epigenetic therapy to durably suppress oncogenic transcriptional networks in GBM.

cancer biology↗

Balanced SET levels favor the correct enhancer repertoire during cell fate acquisition

Within the chromatin, distal elements interact with promoters to regulate specific transcriptional programs. Histone acetylation, interfering with the net charges of the nucleosomes, is a key player in this regulation. Here, we report that the onco-protein SET is a critical determinant for the levels of histone acetylation within enhancers. We disclose that conditions in which SET is accumulated, including the severe Schinzel-Giedion Syndrome (SGS), are characterized by a failure in the usage of the distal regulatory regions typically employed during fate commitment. This is accompanied by the usage of alternative enhancers leading to a massive rewiring of the distal control of the gene transcription. This represents a (mal)adaptive mechanism that, on one side, allows to achieve a certain degree of differentiation, while on the other affects the fine and corrected maturation of the cells. Thus, we propose the differential in cis-regulation as a contributing factor to the pathological basis of the SET-related disorders in humans, including SGS, neurodevelopmental disorders, myeloproliferative diseases, and cancer.

developmental biology↗